Products
Glembatumumab Vedotin Biosimilar Antibody-Drug Conjugate (GPNMB) for Research
Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Glembatumumab vedotin (also known as CDX-11 and CR11-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-856-1mg | 1mg | 4635 |
| GMP-Bios-INN-856-10mg | 10mg | |
| GMP-Bios-INN-856-100mg | 100mg | |
| GMP-Bios-INN-856-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Glembatumumab Vedotin Biosimilar, Whole Mab Adc, Anti-Gpnmb Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody Drug Conjugate |
| INN Name | Glembatumumab Vedotin |
| Target | GPNMB |
| Format | Whole mAb ADC |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG2 - kappa |
| VD LC | IgG2 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Celldex Therapeutics, Inc. (Needham MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Abgenix's XenoMouse® |
About target - GPNMB
1. Protein Transmembrane glycoprotein NMB
2. Gene GPNMB
3. Organism Homo sapiens (Human)
Function
Could be a melanogenic enzyme.
